• Je něco špatně v tomto záznamu ?

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

F. Cavanna, S. Muller, LA. de la Fuente, F. Zamberlan, M. Palmucci, L. Janeckova, M. Kuchar, C. Pallavicini, E. Tagliazucchi

. 2022 ; 12 (1) : 307. [pub] 20220802

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024943

The use of low sub-perceptual doses of psychedelics ("microdosing") has gained popularity in recent years. Although anecdotal reports claim multiple benefits associated with this practice, the lack of placebo-controlled studies severely limits our knowledge of microdosing and its effects. Moreover, research conducted in standard laboratory settings could fail to capture the motivation of individuals engaged or planning to engage in microdosing protocols, thus underestimating the likelihood of positive effects on creativity and cognitive function. We recruited 34 individuals starting to microdose with psilocybin mushrooms (Psilocybe cubensis), one of the materials most frequently used for this purpose. Following a double-blind placebo-controlled experimental design, we investigated the acute and short-term effects of 0.5 g of dried mushrooms on subjective experience, behavior, creativity (divergent and convergent thinking), perception, cognition, and brain activity. The reported acute effects were significantly more intense for the active dose compared to the placebo, but only for participants who correctly identified their experimental condition. These changes were accompanied by reduced EEG power in the theta band, together with preserved levels of Lempel-Ziv broadband signal complexity. For all other measurements there was no effect of microdosing except for few small changes towards cognitive impairment. According to our findings, low doses of psilocybin mushrooms can result in noticeable subjective effects and altered EEG rhythms, but without evidence to support enhanced well-being, creativity and cognitive function. We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024943
003      
CZ-PrNML
005      
20221031101116.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41398-022-02039-0 $2 doi
035    __
$a (PubMed)35918311
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cavanna, Federico $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina $u Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Montañeses 2325, C1428 CABA, Buenos Aires, Argentina
245    10
$a Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study / $c F. Cavanna, S. Muller, LA. de la Fuente, F. Zamberlan, M. Palmucci, L. Janeckova, M. Kuchar, C. Pallavicini, E. Tagliazucchi
520    9_
$a The use of low sub-perceptual doses of psychedelics ("microdosing") has gained popularity in recent years. Although anecdotal reports claim multiple benefits associated with this practice, the lack of placebo-controlled studies severely limits our knowledge of microdosing and its effects. Moreover, research conducted in standard laboratory settings could fail to capture the motivation of individuals engaged or planning to engage in microdosing protocols, thus underestimating the likelihood of positive effects on creativity and cognitive function. We recruited 34 individuals starting to microdose with psilocybin mushrooms (Psilocybe cubensis), one of the materials most frequently used for this purpose. Following a double-blind placebo-controlled experimental design, we investigated the acute and short-term effects of 0.5 g of dried mushrooms on subjective experience, behavior, creativity (divergent and convergent thinking), perception, cognition, and brain activity. The reported acute effects were significantly more intense for the active dose compared to the placebo, but only for participants who correctly identified their experimental condition. These changes were accompanied by reduced EEG power in the theta band, together with preserved levels of Lempel-Ziv broadband signal complexity. For all other measurements there was no effect of microdosing except for few small changes towards cognitive impairment. According to our findings, low doses of psilocybin mushrooms can result in noticeable subjective effects and altered EEG rhythms, but without evidence to support enhanced well-being, creativity and cognitive function. We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.
650    12
$a Agaricales $7 D000363
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a halucinogeny $x farmakologie $7 D006213
650    _2
$a lidé $7 D006801
650    _2
$a motivace $7 D009042
650    _2
$a psilocybin $x farmakologie $7 D011562
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Muller, Stephanie $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina
700    1_
$a de la Fuente, Laura Alethia $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina $u Institute of Cognitive and Translational Neuroscience, INECO Foundation, Favaloro University, Buenos Aires, Argentina $1 https://orcid.org/0000000256891709
700    1_
$a Zamberlan, Federico $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina $u Department of Cognitive Science and Artificial Intelligence, Tilburg University, Tilburg, the Netherlands
700    1_
$a Palmucci, Matías $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina
700    1_
$a Janeckova, Lucie $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic
700    1_
$a Kuchar, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic $1 https://orcid.org/0000000276166352
700    1_
$a Pallavicini, Carla $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina $u Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Montañeses 2325, C1428 CABA, Buenos Aires, Argentina
700    1_
$a Tagliazucchi, Enzo $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina. tagliazucchi.enzo@googlemail.com $u Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibañez, Santiago de Chile, Chile. tagliazucchi.enzo@googlemail.com $1 https://orcid.org/0000000304219993
773    0_
$w MED00177206 $t Translational psychiatry $x 2158-3188 $g Roč. 12, č. 1 (2022), s. 307
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35918311 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101112 $b ABA008
999    __
$a ok $b bmc $g 1854571 $s 1176233
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 1 $d 307 $e 20220802 $i 2158-3188 $m Translational psychiatry $n Transl Psychiatr $x MED00177206
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...